➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Baxter
Mallinckrodt
McKesson
Express Scripts

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ifetroban


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ifetroban?

Ifetroban is an investigational drug.

There have been 9 clinical trials for Ifetroban. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2019.

The most common disease conditions in clinical trials are Respiratory Tract Diseases, Respiration Disorders, and Hypertension. The leading clinical trial sponsors are Cumberland Pharmaceuticals, Brigham and Women's Hospital, and Jeffrey Rade.

There are seven hundred and four US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Ifetroban
TitleSponsorPhase
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionAmerican Heart AssociationPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionCumberland PharmaceuticalsPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionJeffrey RadePhase 2

See all Ifetroban clinical trials

Clinical Trial Summary for Ifetroban

Top disease conditions for Ifetroban
Top clinical trial sponsors for Ifetroban

See all Ifetroban clinical trials

US Patents for Ifetroban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ifetroban   Get Started Free Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Get Started Free
Ifetroban   Get Started Free Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA)   Get Started Free
Ifetroban   Get Started Free Compositions and methods of treating cardiac fibrosis with ifetroban Cumberland Pharmaceuticals Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   Get Started Free
Ifetroban   Get Started Free Substituted biaryl sulfonamides and the use thereof NovoMedix, LLC (San Diego, CA)   Get Started Free
Ifetroban   Get Started Free Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists Cumberland Pharmaceuticals, Inc. (Nashville, TN) Vanderbilt University (Nashville, TN)   Get Started Free
Ifetroban   Get Started Free (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases MEI PHARMA, INC. (San Diego, CA)   Get Started Free
Ifetroban   Get Started Free Diacylglycerol acyl transferase 2 inhibitors Pfizer Inc. (New York, NY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ifetroban

Drugname Country Document Number Estimated Expiration Related US Patent
Ifetroban China CN103987697 2031-10-14   Get Started Free
Ifetroban European Patent Office EP2766345 2031-10-14   Get Started Free
Ifetroban European Patent Office EP2899183 2031-10-14   Get Started Free
Ifetroban Spain ES2572908 2031-10-14   Get Started Free
Ifetroban Spain ES2699226 2031-10-14   Get Started Free
Ifetroban India IN2806CHN2014 2031-10-14   Get Started Free
Ifetroban Japan JP2014528479 2031-10-14   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.